Kostadinova I, Simeonova A
Clinical Centre of Nuclear Medicine and Radiotherapy, Medical Faculty, Sofia, Bulgaria.
Nucl Med Commun. 1995 Mar;16(3):128-31.
The purpose of this study was to evaluate the new renal radiopharmaceutical 99Tcm-N,N-ethylene-L-dicysteine (99Tcm-EC) in patients with hypertension, applying the captopril test. Twelve controls, 45 patients with essential hypertension (EH) and 8 with renovascular hypertension (RVH) were investigated. The captopril test was assessed using different parameters of kidney function. In the controls they were: Tmax 3.33 min, T1/2 9.27 min, retention index 0.30. In the patients with EH they were: before captopril Tmax 4.87 min, T1/2 16.35 min, retention index 0.41; after captopril Tmax 4.19 min, T1/2 13.78 min, retention index 0.40. In the patients with RVH they were: before captopril Tmax 6.50 min, T1/2 not reached, retention index 0.70; after captopril Tmax 9.33 min, T1/2 not reached, retention index 0.90. Our results indicate that this new renal radiopharmaceutical can be reliably used for carrying out the captopril test in patients with hypertension, in order to screen those with RVH.
本研究的目的是通过卡托普利试验，评估新型肾放射性药物99锝-N，N-乙烯-L-二巯基丁二酸（99锝-EC）在高血压患者中的应用情况。对12名对照者、45名原发性高血压（EH）患者和8名肾血管性高血压（RVH）患者进行了研究。使用不同的肾功能参数评估卡托普利试验。对照者的参数为：最大时间（Tmax）3.33分钟，半衰期（T1/2）9.27分钟，滞留指数0.30。EH患者的参数为：服用卡托普利前Tmax 4.87分钟，T1/2 16.35分钟，滞留指数0.41；服用卡托普利后Tmax 4.19分钟，T1/2 13.78分钟，滞留指数0.40。RVH患者的参数为：服用卡托普利前Tmax 6.50分钟，未达到T1/2，滞留指数0.70；服用卡托普利后Tmax 9.33分钟，未达到T1/2，滞留指数0.90。我们的结果表明，这种新型肾放射性药物可可靠地用于高血压患者的卡托普利试验，以筛查RVH患者。
